Illumina Inc. ($ILMN) Stock Forecast: Up 5.1% Today

What is Illumina Inc.?

Illumina (ILMN) is a leading company in the genomics industry, providing innovative solutions for genetic research and precision medicine. The stock had a strong bullish movement today amidst positive market sentiment.

Why is Illumina Inc. going up?

ILMN stock is up 5.1% on Jan 21, 2026 15:25

• Illumina's stock surged today following the news of securing CMS reimbursement for its TruSight Oncology Comprehensive test at $2,989.55 per test, effective January 1, 2026. This reimbursement is expected to drive adoption of the test, boosting Illumina's market share and revenue.
• The partnership with pharma giants like AstraZeneca, Merck, and Eli Lilly to map disease biology at an unprecedented scale through the Billion Cell Atlas initiative also contributed to the bullish movement. This collaboration enhances Illumina's position in the precision medicine field and strengthens its role in accelerating drug discovery processes.
• Analysts' positive outlook on Illumina's earnings growth and target price increases from firms like TD Cowen and Guggenheim further fueled investor optimism, driving the stock higher.
• Illumina's focus on offering integrated genomic workflow solutions for genetic disease research and emphasizing scalable informatics and high-quality genomic data generation also added to the positive market sentiment, showcasing the company's commitment to innovation and advancement in the genomics industry.

ILMN Price Chart

ILMN Technical Analysis

ILMN News

Illumina Secures CMS Reimbursement for TruSight Oncology Test at $2,989.55

Illumina has secured CMS reimbursement for its TruSight Oncology Comprehensive test at $2,989.55 per test, effective January 1, 2026, which is expected to boost adoption and market share. The test analyzes over 500 genes for oncology treatment decisions, addressing a growing market need. Despite a high P/E ratio, analysts anticipate 28% earnings growth, leading to increased target prices from firms like TD Cowen and Guggenheim as market sentiment remains optimistic for Illumina.

https://intellectia.ai/news/stock/illumina-secures-cms-reimbursement-for-trusight-oncology-test-at-298955

Medicare to cover $2,989.55 Illumina genomic cancer test

Illumina has received CMS reimbursement for its FDA-approved TruSight™ Oncology Comprehensive (TSO Comprehensive) test, set at $2,989.55 per test, effective January 1, 2026. This decision establishes a clear and predictable Medicare payment pathway, aiming to expand access to precision oncology by enabling more laboratories to offer in-house comprehensive genomic profiling. The reimbursement is expected to drive further adoption of the test within the U.S. healthcare system, supporting Illumina's clinical focus which contributed approximately 60% of its sequencing consumables revenue in 2025.

https://www.stocktitan.net/news/ILMN/illumina-secures-cms-reimbursement-for-tru-sight-tm-oncology-3ttivtewtdxz.html

Genetic Disease Research Solutions

Illumina offers integrated genomic workflow solutions for genetic disease research, covering discovery, characterization, and interpretation. These solutions combine trusted sequencing technologies with scalable informatics to generate high-quality genomic data and translate it into biological insights. The approach emphasizes streamlined, scalable, and flexible strategies from sample preparation to data analysis for both whole-exome and whole-genome sequencing.

https://www.illumina.com/solutions/genetic-disease-research-solutions.html

Illumina partners with pharma giants to map disease biology at unprecedented scale

Illumina has launched the Billion Cell Atlas, an initiative to create the world's largest genome-wide genetic perturbation dataset, in collaboration with AstraZeneca, Merck, and Eli Lilly. This three-year project aims to map five billion human cells to accelerate drug discovery by providing a clearer understanding of disease mechanisms and strengthening AI model training for precision medicine. The dataset will track how individual cells respond to genetic changes across over 200 disease-relevant cell lines, facilitating the identification of new drug targets and disease indications.

https://mugglehead.com/illumina-partners-with-pharma-giants-to-map-disease-biology-at-unprecedented-scale/

Trending Today

Bitcoin ($BTC) Crypto Forecast: Down 6.9% Today

Ethereum ($ETH) Crypto Forecast: Down 11.1% Today

XRP ($XRP) Crypto Forecast: Down 5.4% Today

Cardano ($ADA) Crypto Forecast: Down 5.6% Today

Illumina Inc. Price History

20.00.2026 - ILMN Stock was up 5.1%

• The bullish movement in Illumina's stock could be attributed to the company's partnership with pharma giants like AstraZeneca, Merck, and Eli Lilly to launch the Billion Cell Atlas initiative. This ambitious project aims to map genetic perturbations in five billion human cells, providing valuable insights for drug discovery and precision medicine.
• The collaboration with major pharmaceutical companies highlights Illumina's commitment to advancing genomic research and its potential to revolutionize the field of AI-driven drug discovery.
• The emphasis on creating a comprehensive genetic dataset to accelerate drug discovery and improve target validation likely resonated positively with investors, driving the bullish market movement in Illumina's stock today.

20.00.2026 - ILMN Stock was up 5.2%

• The bullish movement in Illumina's stock today is due to Medicare's decision to cover the TruSight™ Oncology Comprehensive test, enabling a clear reimbursement pathway and broadening access to precision oncology. This development is expected to significantly boost Illumina's revenue and enhance investor confidence in the company's clinical focus.
• Illumina's collaboration with major pharmaceutical companies like AstraZeneca, Merck, and Eli Lilly on the Billion Cell Atlas initiative is a testament to its dedication to advancing drug discovery and precision medicine by mapping disease biology at an unprecedented scale. This partnership underscores Illumina's leading position in genomic research and innovation, strengthening its market presence and growth potential.
• The company's integrated genomic workflow solutions for genetic disease research, which prioritize high-quality genomic data generation and interpretation, also contribute to its positive market sentiment. Illumina's holistic approach to genetic research and emphasis on scalable informatics are resonating well with investors, fueling optimism about the company's future prospects in the genomics industry.

16.09.2025 - ILMN Stock was up 5.2%

• The reasons behind the bullish movement in ILMN stock are:
• Favorable comparisons with another stock, potentially positioning ILMN as the more valuable choice.
• Investors seeking promising opportunities in the market may have been attracted by this comparison, resulting in heightened buying activity for ILMN shares.
• Positive perceptions of ILMN's technology and competitive position compared to its rival could have spurred increased demand for the stock.

21.00.2026 - ILMN Stock was up 5.1%

• Illumina's stock surged today following the news of securing CMS reimbursement for its TruSight Oncology Comprehensive test at $2,989.55 per test, effective January 1, 2026. This reimbursement is expected to drive adoption of the test, boosting Illumina's market share and revenue.
• The partnership with pharma giants like AstraZeneca, Merck, and Eli Lilly to map disease biology at an unprecedented scale through the Billion Cell Atlas initiative also contributed to the bullish movement. This collaboration enhances Illumina's position in the precision medicine field and strengthens its role in accelerating drug discovery processes.
• Analysts' positive outlook on Illumina's earnings growth and target price increases from firms like TD Cowen and Guggenheim further fueled investor optimism, driving the stock higher.
• Illumina's focus on offering integrated genomic workflow solutions for genetic disease research and emphasizing scalable informatics and high-quality genomic data generation also added to the positive market sentiment, showcasing the company's commitment to innovation and advancement in the genomics industry.

06.00.2026 - ILMN Stock was up 5.3%

• In spite of regulatory challenges and cautious sentiment from investors, Illumina demonstrated significant bullish momentum today.
• While receiving "hold" ratings from Wall Street Zen and Zacks Research, the company surpassed Q3 earnings projections and offered optimistic FY2025 guidance, resonating well with investors.
• The positive market response can be linked to hopeful investor sentiment regarding Illumina's anticipated recovery, supported by its strategic capital allocation and increasing demand for sequencing.
• Illumina's efforts to adapt to the AI era and consolidate its place in the genomics sector have instilled a sense of cautious optimism among investors and insiders about the company's future trajectory.

05.10.2025 - ILMN Stock was up 5.3%

• Following the company's surpassing of its third-quarter guidance and the narrowing of its full-year revenue decline forecast, Illumina's stock rose by over 23%, indicating optimistic growth prospects.
• Investor sentiment towards Illumina turned positive, with notable investors showing confidence in the company's future performance.
• The third-quarter earnings report exceeded expectations, reporting adjusted earnings of $1.34 per share, surpassing consensus estimates and contributing to the stock's significant increase.
• Illumina's ability to outperform expectations in both earnings and revenue for the quarter ended September 2025 showcases robust operational performance and potential for further growth in the genomics sector.

08.09.2025 - ILMN Stock was down 5.5%

• The bearish movement in ILMN today could be attributed to profit-taking by investors after a period of strong performance.
• The upcoming earnings report, despite expectations of a beat, might have led to some uncertainty among investors, causing a sell-off.
• The partnership with pharma companies for CDx development is a positive long-term move, but short-term investors might be reacting cautiously to the news, contributing to the bearish trend.
• Overall, the bearish movement in ILMN today seems to be a short-term market correction rather than a reflection of the company's fundamentals.

31.09.2025 - ILMN Stock was up 14.2%

• Exceeded earnings and revenue expectations for the third quarter.
• Positive surprise indicates strong demand for its products and services.
• Investors are optimistic about its future outlook.
• Market's bullish movement on ILMN today could be attributed to strong financial performance and growth opportunities in the genomics industry.

31.09.2025 - ILMN Stock was up 23.9%

• Illumina's stock soared today following better-than-expected third-quarter earnings.
• The company reported adjusted earnings of $1.34 per share, exceeding the consensus of $1.17, which contributed to the bullish movement.
• Positive earnings and revenue surprises of +15.52% and +1.73%, respectively, for the quarter ended September 2025, further fueled investor confidence in Illumina's growth prospects.
• Overall, the strong financial performance and optimistic outlook from Illumina's earnings likely drove the bullish movement in the stock today.

31.09.2025 - ILMN Stock was up 25.0%

• Illumina's stock surged due to better-than-expected third-quarter earnings, with adjusted earnings surpassing consensus estimates.
• The bullish sentiment towards Illumina was further reinforced by deep-pocketed investors adopting a positive approach towards the company, as revealed by options trading data.
• The company's ability to beat both earnings and revenue estimates for the third quarter showcased its strong performance and potential for future growth, contributing to the stock's upward momentum.
• Overall, Illumina's impressive financial results and market sentiment drove the stock higher, indicating investor confidence in the company's strategic direction and growth prospects in the DNA sequencing industry.

09.11.2025 - ILMN Stock was up 3.2%

• The bullish movement of Illumina is linked to its active participation and partnerships at the 2025 CIIE, showcasing its commitment to the Chinese market and highlighting potential growth opportunities.
• The recent share price rebound and positive gains over 30 and 90 days indicate investor confidence in Illumina's future prospects, despite some fluctuations over the past year.
• Analysts' mixed views on Illumina's valuation suggest ongoing debates regarding the stock's pricing, with considerations around future growth expectations and cash flow trajectory influencing investor sentiment.

09.00.2026 - ILMN Stock was down 5.1%

• Today's bearish movement in Illumina's stock value might stem from concerns over regulatory challenges and changes in investor sentiment.
• The recent introduction of Illumina Connected Multiomics, a robust software platform for simplifying multiomic analysis in precision medicine, aimed to drive faster discovery. However, it might not have sufficiently addressed worries regarding the company's divestment plans and market demand uncertainties.
• Despite surpassing Q3 earnings expectations and offering promising FY2025 guidance, Illumina saw a downgrade to a "hold" rating by Wall Street Zen. This action could have influenced the stock's decline as investors rethought their positions.
• The anticipated rapid growth of the DNA Test Kits Market suggests a favorable industry forecast. Nevertheless, Illumina's performance might have been eclipsed by broader market dynamics and company-specific concerns.